Is Avai Bio, Inc. (AVAI) a Buy, Sell, or Hold?
OTC : AVAI
Avai Bio, Inc. — News
$0.12 USD
-$0.01 (-4.0%)
- Volume
- 18.77K
- Average Volume
- 129.04K
- Market Capitalization
- $16.59M
- P/E Ratio
- -9.52
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.80
- Year Low
- $0.11
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.03
| Source | Headline |
|---|---|
|
Avant Brands Completes Major LED Lighting Retrofit at its 80,000 Sq Ft Flowr Facility, Delivering Significant Energy Savings & Production Gains
KELOWNA, BC / ACCESS Newswire / July 22, 2026 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU) ("Avant" or the "Company"), is pleased to announce the successful completion of a comprehensive facility-wide lighting retrofit at the Company's largest cultivation facility, The Flowr Group Okanagan Inc. ("Flowr"), located in Kelowna, B.C. The project replaced traditional high-pressure sodium (HPS) fixtures with energy-efficient LED lighting across 100% of flower rooms, supported by funding from a Government of British Columbia energy efficiency incentive program. accessnewswire.com - 2026-07-22 07:30:00 |
|
Avaí Bio and Austrianova Reach Agreement for Insulin-Producing Cells with Internationally Acclaimed Partner to Advance Diabetes Therapy
LAS VEGAS, July 21, 2026 /PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced that, together with its joint venture partner Austrianova, it has successfully concluded negotiations and reached agreement on the terms of a collaboration with a premier, internationally acclaimed, partner to provide insulin-producing cells for Insulinova's groundbreaking diabetes therapy. Insulinova is a joint venture (JV) between Avaí and Austrianova, established in late 2025 to develop a revolutionary cell-based therapy for diabetes. prnewswire.com - 2026-07-21 08:00:00 |
|
Avant Brands Reports Q2 2026 Results Highlighted by 34% Growth in Recreational Revenue
KELOWNA, BC / ACCESS Newswire / July 15, 2026 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU0) ("Avant" or the "Company"), a leading producer of innovative and award-winning cannabis products, today released its financial results for the second quarter ended May 31, 2026 ("Q2 2026"). With an expanding global footprint, Avant has established itself as a leading Canadian producer of ultra-premium cannabis, delivering brands at a commercial volume that continues to be outpaced by market demand. accessnewswire.com - 2026-07-15 08:30:00 |
|
Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy
LAS VEGAS, May 20, 2026 /PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's path to clinical trials, the completion of a Master Cell Bank (MCB) of genetically modified cells that overexpress the α-Klotho protein. Now, the MCB will undergo comprehensive testing to confirm the absence of pathogenic viruses, as well as standard assays to verify the MCB is free from adventitious agents such as bacteria, mycoplasma, fungi, and yeast to meet regulatory expectations, including those set by the FDA. prnewswire.com - 2026-05-20 08:45:00 |
